Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through

Y Wang1, Y Yu, A Tsuyada

  • 1Division of Tumor Cell Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.

Oncogene
|November 25, 2010
PubMed

Insights

Transforming growth factor-beta (TGF-β) promotes cancer stem cell (CSC) properties in breast cancer by upregulating miR-181, which suppresses the tumor suppressor ATM. This pathway highlights a novel mechanism regulating CSCs and potential therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Cancer stem cells (CSCs) drive tumor initiation, metastasis, and therapy resistance.
  • Transforming growth factor-beta (TGF-β) signaling is implicated in both normal and cancer stem cells.

Purpose of the Study:

  • To investigate the role of TGF-β in regulating breast cancer stem cell properties.
  • To elucidate the molecular mechanisms by which TGF-β influences CSCs.

Main Methods:

  • Exposure of breast cancer cells to TGF-β and assessment of mammosphere formation.
  • Quantification of miR-181 family members and ATM expression.
  • Genetic manipulation of miR-181, ATM, and CHK2.
  • In vivo tumorigenesis assays.

Main Results:

  • TGF-β increased mammosphere formation in breast cancer cells, mediated by miR-181 upregulation.
  • miR-181 levels were elevated in mammospheres, correlating with decreased ATM expression.
  • Overexpression of miR-181 or depletion of ATM/CHK2 induced sphere formation.
  • ATM knockdown enhanced in vivo tumorigenesis.

Conclusions:

  • The TGF-β pathway regulates CSC properties by downregulating the tumor suppressor ATM via miR-181.
  • This mechanism provides insights into CSC regulation and potential therapeutic strategies targeting CSCs.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...